An Open-Label Two-way Interaction Clinical Trial to Evaluate the Pharmacokinetic Interactions Between GSK3640254 and Dolutegravir in Healthy Subjects
Latest Information Update: 03 Jul 2023
At a glance
- Drugs Dolutegravir (Primary) ; Fipravirimat (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Pharmacokinetics
- Sponsors ViiV Healthcare
Most Recent Events
- 03 Feb 2021 Results published in the British Journal of Clinical Pharmacology.
- 27 Jun 2019 Status changed from recruiting to completed.
- 12 Feb 2019 Status changed from not yet recruiting to recruiting.